Catalyst Wire Dossier Catalyst Wire Dossier

Burfiralimab

Burfiralimab · ImmuneMed, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Burfiralimab, covering 2023-06-15 to 2024-03-12. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug) [Phase 2]

See pricing